Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients
Yusuke Okuma1, Kei Morikawa2, Hisashi Tanaka3
1Departments of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Abstract:
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) exhibit resistance to EGFR-tyrosine kinase inhibitors (TKIs) within 9-14 months of therapy. Recently, EGFR-mutated NSCLC has demonstrated the potential for heterogeneity; therefore, the manner of clonal heterogeneity may impact the duration of progression-free and overall survival and other parameters affecting EGFR-TKI treatment efficacy. However no predictive biomarker of these favorable treatment efficacies has been identified to date. The exosome-focused translational research for afatinib (EXTRA) study aims to identify a novel predictive biomarker and a resistance marker for afatinib by analyzing data from association studies of the clinical efficacy of afatinib and four "OMICs" (genomics, proteomics, epigenomics, and metabolomics) using peripheral blood from patients treated with afatinib. This study aims to: (i) conduct comprehensive multi-OMIC analyses in a prospective clinical trial, and (ii) focus on both sera/plasma and exosome as a source for OMIC analyses to identify a novel predictor of the efficacy of a specific drug. To eliminate the carryover bias of prior treatment, systemic treatment-naïve patients were enrolled. The candidates to be screened for biomarkers comprise a discovery cohort of 60 patients and an independent validation cohort of 40 patients. The EXTRA study is the first trial to screen novel biomarkers of longer treatment efficacy of EGFR-TKIs using four-OMICs analyses, focusing on both "naked or free" molecules and "capsulated" exosomal components in serially collected peripheral blood.
Insights
Researchers are seeking new biomarkers to predict how well patients with EGFR-mutated non-small cell lung cancer (NSCLC) respond to afatinib. The EXTRA study analyzes multi-omics data from blood and exosomes to find these crucial predictive markers.
Area of Science:
- Oncology
- Translational Research
- Biomarker Discovery
Background:
- EGFR-mutated non-small cell lung cancer (NSCLC) patients develop resistance to EGFR-tyrosine kinase inhibitors (TKIs) typically within 9-14 months.
- Tumor clonal heterogeneity in EGFR-mutated NSCLC may influence treatment efficacy and patient survival, but predictive biomarkers are lacking.
- Identifying reliable biomarkers is crucial for optimizing EGFR-TKI therapy and improving patient outcomes.
Purpose of the Study:
- To identify novel predictive and resistance biomarkers for afatinib in EGFR-mutated NSCLC.
- To analyze comprehensive multi-omics data (genomics, proteomics, epigenomics, metabolomics) from peripheral blood.
- To investigate both cell-free and exosome-encapsulated molecules for biomarker potential.
Main Methods:
- The EXTRA study prospectively analyzes peripheral blood from systemic treatment-naïve patients.
- Multi-omics analyses are performed on both serum/plasma and exosomes.
- A discovery cohort of 60 patients and a validation cohort of 40 patients are utilized.
Main Results:
- This is the first trial to employ a multi-omics approach for screening EGFR-TKI efficacy biomarkers.
- The study investigates both free and exosomal molecules in serially collected blood samples.
- Analysis focuses on identifying predictors of longer treatment efficacy for EGFR-TKIs.
Conclusions:
- The EXTRA study aims to establish a novel predictive biomarker for afatinib efficacy in EGFR-mutated NSCLC.
- Comprehensive multi-omics profiling of blood and exosomes holds promise for personalized cancer therapy.
- Identifying biomarkers can guide treatment decisions and improve survival for NSCLC patients.
More Related Videos
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
01:22Case Studies
01:31Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
01:58Cell Specific Gene Expression
02:33Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...